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Background: Age-related macular degeneration (AMD) is the leading cause of irreversible visual
impairment and blindness among persons aged 60 years and older. Although inﬂammation has been
postulated to have a role in the pathogenesis of AMD, epidemiologic studies have not shown a rela-
tionship between systemic inﬂammation or presence of inﬂammatory markers at AMD. The aim of our
study was to evaluate the differences in various types of cytokines and intracelluler signaling molecules
for the onset and progression of AMD.
Materials and methods: There were two groups in our study; Group 1, which acted as the control group
(n¼ 30, mean age 67.60 8.32 years), and Group 2, consisting of AMD patients (n¼ 22, mean age
70.10 10.33 years). From serum samples, vascular endothelial growth factor (VEGF) (pg/mL), inter-
leukin-6 (IL-6) and interleukin-1b (IL-1b) (pg/mL), nitrotyrosine (nmol/L) levels were determined by
enzyme linked-immuno-sorbent assay method. Nitrite/Nitrate levels were measured by photometric
method (mmol/L).
Results: There were no signiﬁcant differences between the groups with regard to age, VEGF, IL-1b, nitrite/
nitrate, and nitrotyrosine. The signiﬁcant result was the mean IL-6 levels that were higher in the AMD
group (55.03 60.03 pg/mL) than in the control group (16.08 8.24 pg/mL, p< 0.001).
Conclusion: IL-6 induces an ocular inﬂammatory response often accompanied by the breakdown of the
bloodeocular barrier. The increased levels of IL-6 can support the hypothesis that AMD may be partially
mediated through inﬂammatory mechanisms.
Copyright  2012, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Age-related macular degeneration (AMD) is the leading cause of
irreversible visual impairment among adults aged60 years and over1.
Complications of the disease include choroidal neovascularization
(CNV), and subsequent bleeding and exudation of the macula,
leading to severe vision loss and blindness2. All around theworld, the
elderly population is growing and the problem of the loss of visual
function is also steadily increasing. Treatment options for this
pervasive problem (AMD) are limited, and prevention remains the
best approach1.ncial involvement, within the
n or entity with a ﬁnancial
or materials discussed in the
ut Public Health Laboratory,
irim).
iwan Society of Geriatric EmergenInﬂammation has been postulated to play a role in the patho-
genesis of AMD3e5. Besides endothelial dysfunction resulting from
inﬂammation and hypertension, cigarette smoking has also been
postulated to be involved in the pathogenesis of AMD6.
An early and important sign of AMD is drusen, which is an
extracellular deposit that accumulate in the retinal pigment
epithelium7. Epidemiological studies have shown that numerous
and/or conﬂuent drusen signiﬁcantly increase the risk for devel-
oping AMD8. Hageman and associates4 have shown that drusen
contain proteins associated with immune-mediated process and
inﬂammation. Additionally, chronic inﬂammatory cells have been
observed on the outer surface of the Bruch’s membrane in eyes
with neovascular macular degeneration3. These cells may cause
atherogenesis and microvascular injury through the direct release
of long-acting oxidants as toxic oxygen compounds, and proteolytic
enzymesmay also damage the Bruch’s membrane9. The presence of
biogenesis, composition of drusen (yellowish deposits) in the
macula, has been studied in relationwith inﬂammation. It has been
hypothesized that large and soft drusen can confer a higher risk ofcy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
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local inﬂammatory events in the eye4,5,11e13.
However, data from epidemiologic studies have not shown any
relationship between systemic inﬂammation and presence of
inﬂammatory markers at AMD14e16. Interleukin-6 (IL-6), a potent
proinﬂammatory and multifunctional cytokine, is suggested to be
a risk factor for CNV because of its increased levels in the serum of
patients with AMD; however, the role of IL-6 in CNV has not been
deﬁned17. IL-6 may also indirectly cause an increase of vascular
permeability by inducing the expression of vascular endothelial
growth factor (VEGF)17 or may directly increase endothelial
permeability18. VEGFs have been implicated in the pathogenesis of
CNV secondary to AMD. There is, however, evidence that intercel-
lular signaling molecules, such as nitric oxide (NO), are also
involved in this process. NO is synthesized via the inducible isoform
of NO synthase, which is expressed after induction by cytokines19.
The levels of VEGF, whose effects can be mediated via other
factors/cytokines and different inﬂammatory mediators/cytokines
such as IL-6, interleukin-1b (IL-1b), nitrite/nitrate, and nitro-
tyrozine, were evaluated in order to study how they contribute in
the pathogenesis of AMD. The aim of this study was to evaluate the
multiple risk factors for the onset and progression of AMD via the
inﬂammatory process.
2. Material and methods
We designed two groups in our study. The ﬁrst group was the
control group, with 13 females and 17 males (n¼ 30, age range
51e80 years), and the second group consisted of patients with
choroidal neovascular membrane in AMD,with eight females and 14
males (n¼ 22, age range 50e90 years). Patients with other
ophthalmic conditions (e.g., glaucoma, uveitis, pseudoexfoliation
syndrome, progressive other retinal disease) and systemic diseases
(e.g., diabetes, arthritis, coronary arterial disease, peripheral
vascular disease) were excluded. All patients underwent a compre-
hensive ophthalmic examination. The CNV was determined by slit-
lamp biomicroscopes of the fundi, color fundus photographs, fundus
ﬂuorescein angiography, and optical coherence tomography. The
control individuals have totally normal ophthalmic condition.
All participants, including controls, ﬁlled out a questionnaire
giving the following information: age, gender, no smoking habits,
no supplements such as vitamins and/or antioxidants. Human
Ethics Committee rules were satisﬁed. Informed consent was
obtained from patients.
Blood samples were drawn from patients and controls after
overnight fasting, before the operation. Blood samples were
centrifuged at 2000g for 10 minutes at 4 C, and serum samples
were stored in the dark at 70 C for further analyses.
2.1. Biochemical parameters
From the serum samples, VEGF levels were determined using
the enzyme-linked immunosorbent assay (ELISA) method Quanti-
kine Immunoassay VEGF; R&D Systems, Minneapolis, MN 55413,
USA, Lot No.: 250498 Cat. No.:RRVOO).
Human IL-6 was determined by a solid-phase sandwich ELISA
(BioSource Immunoassay Kit; BioSource International, Inc.,Table 1
Serum VEGF, IL-6, IL-1b, Nitrit-nitrate, Nitrotyrosine in AMD patients and the control gro
Age VEGF pg/mL IL-6 (pg/mL)
Control (n¼ 30) 67.60 8.32 447.33 220.49 16.08 8.24
AMD (n¼ 22) 70.10 10.33 301.90 134.60 55.03 60.03*
*p¼ 0.002 compared to control group.Camarillo, CA, USA; Cat No: KHCOO61, Lot No: 064903). Human
IL-1b was also determined using the same method (BioSource
Immunoassay Kit; BioSource International, Inc., Cat No: KHCOOII,
Lot No: 064103).
Nitrite/nitrate levels were determined using the colorimetric
method (photometric endpoint determination, Cat. No. 1 746 081,
by Roche kit). The assay principle is that nitrate is reduced to nitrite
by reduced nicotinamide adenine dinucleotide phosphate in the
presence of the enzyme nitrate reductase. The nitrite formed reacts
with sulfanilamide and N-(1-naphtyl)-ethylene-diamine dihydro-
chloride to give a red-violet diazo dye. The diazo dye is measured
on the basis of its absorbance in the visible range at 540 nm20,21.
Nitrotyrosine levels were also analyzed by ELISA kit (Hycult
Biotech, Frontstraat 2a, 5405 PB Uden, the Netherlands, Cat. No.:
HK501, Lot No.: 5419K18).
2.2. Statistical analysis
Data were analyzed using the SPSS 8.0 statistic program (SPSS,
Chicago, IL, USA). Differences in mean values (means) between the
two groups were tested by ManneWhitney U-test. The level of
statistical signiﬁcance was set at p< 0.05.
3. Results
The means and standard deviations for the ages and biochemical
parameters for the AMD group and the control group are listed in
Table 1. There were no signiﬁcant differences between AMD and
control groups with regard to age, VEGF, IL-1b, nitrite/nitrate, and
nitrotyrosine. The only signiﬁcant result was the mean IL-6 levels
that were higher in the AMD group (55.03 60.03 pg/mL) compared
to the control group (16.08 8.24 pg/mL) (p< 0.001) (Table 1).
4. Discussion
AMD is a complex multifactorial disease with an unknown
etiology and pathogenesis22. Inﬂammation is also associated with
angiogenesis and neovascularization that AMD may represent in
chronic, age-related inﬂammatory disease manifested in the eye
and other organs, including the heart and the brain14. Both brain
and retina have an endogenous immune system depending on the
bloodetissue barrier. Moreover, the activation of a complement
pathway which occurs in that environment might result as an
unregulated chronic inﬂammation inducing a common self-
propagating damaging cycle for AMD7.
Our ﬁndings support the hypothesis that AMD may be partially
mediated through inﬂammatory and immune-relatedmechanisms.
Other basic research had suggested that AMD shares biological
pathways similar to those found in other inﬂammatory diseases,
such as Alzheimer disease and atherosclerosis4,5,11e13. AMD can be
classiﬁed as atrophic (dry) or neovascular (wet) forms, both of
which can lead to signiﬁcant visual loss23. Also, CNV associated
with AMD develops after chronic inﬂammation to the retinal
pigment epithelium2. In previous studies of human surgical
samples and animal models, VEGF was shown to be a key molecule
in the development of CNV24,25, and VEGF has recently been
recognized as a proinﬂammatory cytokine in the eye26,27. Inup (mean SD).
IL-1b (pg/mL) Nitrit-nitrate (mmol/L) Nitrotyrosine (nmol/L)
4.54 0.92 4.10 0.74 41.90 7.00
4.48 0.29 4.31 0.76 47.80 32.00
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includingmacrophage inﬁltration and cytokine network26,27, VEGFs
play crucial roles in CNV2. Our ﬁndings on VEGF levels were not
different than those in control groups; however, alterations in IL-6
levels were in agreement with studies supporting the inﬂuence of
inﬂammation. Moreover, Izumi-Nagai et al28, in their in vivo data,
also showed that the IL-6 receptor-dependent activation of
inﬂammatory signaling promotes CNV. Recently, it has been shown
that CNV formation is mediated by IL-6 receptor signaling2.
As a result of local inﬂammation, neutrophil, macrophage, and
mast cells were activated, and all microglia proangiogenic factors,
especially CNV, led to VEGF and TNF-a oscillation29.
The disease activity of CNV in AMD was signiﬁcantly related to
levels of VEGF, IL-2, IL-6, IL-8, and TNF-a30. Roh et al30 found that in
patients who have active CNV, the aqueous humor levels of IL-6 and
IL-8 signiﬁcantly correlated with the size of CNV.
Systemic inﬂammatory markers in higher levels of C-reactive
protein and IL-6 are independently related to progression of AMD1.
VEGF can be a multifunctional cytokine that contributes to
angiogenesis by both direct and indirect mechanisms19. In contrast
to other growth factors which have been isolated from the retina,
VEGF can initiate themajor steps of angiogenesis such as production
and release of collagenase activity by endothelial cells, stimulation
of endothelial cell migration, and stimulation of endothelial cell
proliferation19. It has also been localized in numerous retinal cells
including Müller cells, astrocytes, pericytes, vascular endothelial
cells, and retinal pigment epithelial cells31. IL-6 is also synthesized
by a variety of cells within the eye; the sources of IL-6 include the
retinal pigment epithelial cells, corneal epithelial cells, keratocytes,
iris, and ciliary body32. It is a multifunctional cytokine that may be
a major mediator of anterior uveits and proliferative vitreoretin-
opathy33. IL-6 may indirectly cause an increase of vascular perme-
ability, angiogenesis, and neovascularization by inducing the
expression of VEGF17, or may directly induce an increase of endo-
thelial permeability and new vessel formation18. IL-6 is reported to
induce an ocular inﬂammatory response that is often accompanied
by breakdown of the bloodeocular barrier, as detected by an
increased protein concentration in either the aqueous humor or
vitreous ﬂuid34.
Angiogenic cytokines act in concert with intercellular messen-
gers that modify their action. NO is also known as an important
intercellular signaling molecule that ranks in the vasodilatory
responses of physiological and pathological processes in the
retina35,36 and a potent inhibitor of cytokine-induced proliferation
of microvascular endothelial cells37, suggesting that the production
of NOmay contribute to the regulation of cell growth in proliferative
ocular diseases38. Several recent studies have strongly implicated
VEGF in the pathogenesis of CNV. VEGF-induced angiogenesis,
in vivo, is signiﬁcantly attenuated by NOS inhibition39,40; however,
there is considerable evidence that NO is involved in the endoge-
nous regulation of angiogenesis and endothelial integrity mediated
by VEGF40,41. Cohen and associates17 reported that IL-6 may induce
angiogenesis indirectly via the induction of VEGF expression. The
production of both VEGF and IL-6 is known to be upregulated by
ischemia, advanced glycation end-product, and insulin-like growth
factor-1, and it can be suggested that changes in other cytokines
might also promote the expression of VEGF and IL-642,43.
In our study, we only have to be able to include patients who
were willing to participate in the study so that additional prospec-
tive studies, and possibly randomized clinical trials, can be helpful in
obtaining results and hypotheses that require conﬁrmations.
In treating AMD, several agents that inhibit the action of VEGF
have recently been studied for the treatment of neovascular
diseases. Moreover, the role of inﬂammation in the pathogenesis
and progression of AMD suggests the importance of variouscytokines such as IL-6, IL-8, and IL-10 related to CNV. The results of
recent studies from other laboratories and our recent study have
suggested that local and chronic inﬂammation induced by the
complement pathways plays a central role in the development of
AMD. Moreover, levels of various inﬂammatory biomarkers may
add clinically relevant, predictive information to known, more
well-established risk factors for AMD.References
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